|
|
BRIEF REPORT |
|
|
|
| Year : 2007 | Volume
: 55
| Issue : 1 | Page : 75-76 |
| |
Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity
Parag K Shah1, V Narendran1, Khaled A Tawansy2, A Raghuram1, Kalpana Narendran3
1 Vitreo-Retinal Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India
2 Children's Retina Institute of California, Glendale, USA
3 Pediatric Ophthalmology Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore, Tamil Nadu, India
| Date of Submission | 15-Jul-2006 |
| Date of Acceptance | 17-Oct-2006 |
Correspondence Address:
Parag K Shah
Department of Vitreous and Retina, Aravind Eye Hospital, Avinashi Road, Coimbatore - 641 014, Tamil Nadu
India
  | 31 |
DOI: 10.4103/0301-4738.29505 PMID: 17189897
 Abstract | | |
Aggressive posterior retinopathy of prematurity (formerly known as fulminate/type II/rush disease) occurs in zone 1 or posterior zone 2. Treatment involves extensive near confluent laser ablation of a large area of avascular retina. Anterior segment ischemia is a rare complication that can occur due to injury to the long posterior ciliary arteries in the horizontal meridians during aggressive posterior laser treatment. The outcome of this rare complication is very poor. This case describes a favorable outcome of intravitreal injection of bevacizumab (Avastin) in a case of anterior segment ischemia.
Keywords: Bevacizumab, intravitreal, lamellar cataract, retinopathy of prematurity
How to cite this article:
Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007;55:75-6 |
How to cite this URL:
Shah PK, Narendran V, Tawansy KA, Raghuram A, Narendran K. Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol [serial online] 2007 [cited 2013 Jun 18];55:75-6. Available from: http://www.ijo.in/text.asp?2007/55/1/75/29505 |
Anterior segment ischemia is a rare complication of laser ablation for threshold retinopathy of prematurity (ROP). This invariably results in phthisis.[1],[2] Recently, there has been successful treatment of iris, retinal and choroidal neovascularization with bevacizumab[3],[4] (Avastin, Genentech, San Francisco), a potent inhibitor of vascular endothelial growth factor (VEGF). Herein we report the first case of intravitreal bevacizumab for anterior segment ischemia following retinal ablation for aggressive posterior retinopathy of prematurity (AP-ROP).
| Case Report | |  |
A male twin born at 31 weeks of gestation with birth weight of 1170 g had bilateral AP-ROP on his first screening examination at 2.5 weeks of age. The other twin also had similar ocular findings but unfortunately the baby expired because of unknown cause. The twin was born with invitro fertilization technique after prolonged infertility. Both eyes of the surviving twin received 3,000 spots of near-confluent infrared laser to the avascular retina. One-week postlaser the left eye developed neovascularization of iris (NVI) and mild vitreous haze. We started topical steroids and cyclopegic drops. Ten days postlaser the left eye NVI had increased, posterior synechiae had developed and dense anterior fibrovascular proliferation (FVP) was seen waxy yellow in colour just behind the lens along with hypotony [Figure - 1]a and b. The right eye also started developing early NVI. The vitreous was hazy in both eyes (left eye more than right eye) but retinopathy was regressing [Figure - 2]. Vitreous surgery was offered for the worse eye (left) but declined by the parents due to the poor prognosis. Considering the severity of the disease affecting both eyes and based on promising results with other proliferative retinopathies,[5],[6],[7] an off label use of intravitreal injection of bevacizumab was offered for left eye for which the parents agreed. Under topical anesthesia and aseptic conditions, 0.03 ml (0.75 mg) of bevacizumab was injected intravitreally via a 30-guage needle placed 1mm behind the limbus. At one week follow-up all the NVI had regressed. Weekly examination showed gradual regression of anterior FVP. By Week 10, there was reversal of hypotony, anterior FVP and all NVI [Figure - 3], with a clear view of the fundus showing growth of regression vessels in the lasered retinal periphery [Figure - 4]. There was secondary iris atrophy and mild cataract. No ocular or systemic complications were noted. The right eye became better with hourly and twice a day application of topical steroid and cycloplegic drops respectively. At ten-month follow-up fundus of both eyes showed clear media with well-regressed ROP. Both eyes, however, were seen to develop a lamellar cataract. As the media was clear and retinoscopy was equal in both eyes, the lamellar cataract was just observed.
| Discussion | | |
Anterior segment ischemia may result from thermal injury to the long posterior ciliary arteries in the horizontal meridian. It is the most devastating complication of ablative laser for threshold ROP, a procedure with an otherwise high benefit to risk ratio. Treatment with topical steroids and cycloplegics is insufficient. Vitrectomy with lensectomy and silicone oil injection may be helpful but has a high rate of re-proliferation. Bevacizumab is a full-length antibody, which binds all VEGF isoforms and is approved for intravenous treatment of colorectal cancer. Our patient responded favorably to a single injection of intravitreal bevacizumab and by ten weeks all features of ischemia disappeared.
Intravitreal bevacizumab seemed in this case to strikingly halt the progression of anterior neovascularization, cyclitic membrane formation and hypotony that typically evolves to phthisis. Although it is conceivable that the long posterior ciliary neurovascular injury in this case was not complete and may have improved spontaneously, the prompt resolution of anterior neovascularization postinjection suggests a therapeutic effect. Although we propose that intravitreal bevacizumab may have an important role in the salvation of eyes with dire complications of ROP such as anterior segment ischemia and neovascularization and our patient did not suffer any negative effect on the growth of normal retinal vessels even at ten-month follow up, we urge caution in the generalization of these findings. Formal controlled studies with long-term follow-up are warranted to determine the potential safety and benefit of VEGF inhibitors in ROP that fails conventional therapy.
| References | | |
| 1. | Lambert SR, Capone A Jr, Cingle KA, Drack AV. Cataract and phthsis bulbi after laser photoablation for threshold retinopathy of prematurity. Am J Ophthalmol 2000;129:585-91.  [PUBMED] [FULLTEXT] |
| 2. | Kaiser RS, Trese MT. Iris atrophy, cataracts and hypotony following peripheral ablation for threshold retinopathy of prematurity. Arch Ophthalmol 2001;119:615-7. [PUBMED] [FULLTEXT] |
| 3. | Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-4. [PUBMED] [FULLTEXT] |
| 4. | Spaide RF, Laud K, Fine HF, Klancnik JM, Meyerle CB, Yannuzzi LA, et al . Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age related macular degeneration. Retina 2006;26:383-90. |
| 5. | Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-8. [PUBMED] [FULLTEXT] |
| 6. | Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al . Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina 2006;26:279-84. |
| 7. | Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006;37:144-6. [PUBMED] |
Figures
[Figure - 1], [Figure - 2], [Figure - 3], [Figure - 4]
| This article has been cited by | | 1 |
Anti-VEGF Therapy With Bevacizumab for Anterior Segment Eye Disease : |
|
| Hamid Hosseini, Mohammad H Nowroozzadeh, Ramin Salouti, Mahmood Nejabat | | Cornea. 2012; 31(3): 322 | | [VIEW] | | | 2 |
Effect of Laser Photocoagulation and Intravitreal Bevacizumab Injection on Zone I Retinopathy of Prematurity |
|
| Won Choi, Hwan Heo | | Journal of the Korean Ophthalmological Society. 2012; 53(1): 120 | | [VIEW] | | | 3 |
Intravitreal Bevacizumab for Retinopathy of Prematurity |
|
| Björn C. Harder, Stefan von Baltz, Jost B. Jonas, Frank C. Schlichtenbrede | | Journal of Ocular Pharmacology and Therapeutics. 2011; 27(6): 623 | | [VIEW] | | | 4 |
Mediators involved in retinopathy of prematurity and emerging therapeutic targets |
|
| A. Mataftsi, S.A. Dimitrakos, G.G.W. Adams | | Early Human Development. 2011; | | [VIEW] | | | 5 |
Visual acuity and electroretinography findings 3 1/2 years after the first intravitreal injection of bevacizumab (Avastin) in aggressive posterior retinopathy of prematurity |
|
| Shah, P.K., Morris, R.J., Narendran, V., Kalpana, N. | | Indian Journal of Ophthalmology. 2011; 59(1): 73-74 | | [Pubmed] | | | 6 |
INTRAVITREAL BEVACIZUMAB AS SUPPLEMENTAL TREATMENT OR MONOTHERAPY FOR SEVERE RETINOPATHY OF PREMATURITY : |
|
| Ruth Axer-Siegel, Moshe Snir, Yonina Ron, Ronit Friling, Lea Sirota, Dov Weinberger | | Retina. 2011; 31(7): 1239 | | [VIEW] | | | 7 |
Rescue Intravitreal Bevacizumab (Avastin) for Aggressive Posterior Retinopathy of Prematurity |
|
| Farhan Qureshi, Christopher Dewhurst, C.W. Yoxall, David Clark | | Seminars in Ophthalmology. 2011; 26(2): 55 | | [VIEW] | | | 8 |
Pharmacological treatment of retinopathy of prematurity: antiangiogenic or proangiogenic? |
|
| Akiyoshi Uemura | | Expert Review of Ophthalmology. 2010; 5(2): 123 | | [VIEW] | | | 9 |
New progress on the treatment of retinopathy of prematurity |
|
| Tan, J.-X., Zhu, D. | | International Journal of Ophthalmology. 2010; 10(5): 898-900 | | [Pubmed] | | | 10 |
Pharmacological treatment of retinopathy of prematurity: Antiangiogenic or proangiogenic? |
|
| Uemura, A. | | Expert Review of Ophthalmology. 2010; 5(2): 123-127 | | [Pubmed] | | | 11 |
Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity |
|
| Law, J.C., Recchia, F.M., Morrison, D.G., Donahue, S.P., Estes, R.L. | | Journal of AAPOS. 2010; 14(1): 6-10 | | [Pubmed] | | | 12 |
Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage |
|
| Hossein Nazari, Mehdi Modarres, Mohammad Mehdi Parvaresh, Khalil Ghasemi Falavarjani | | Graefe s Archive for Clinical and Experimental Ophthalmology. 2010; 248(12): 1713 | | [VIEW] | | | 13 |
Intravitreal cysticercosis presenting as neovascular glaucoma |
|
| Ratra, D., Phogat, C., Singh, M., Choudhari, N.S. | | Indian Journal of Ophthalmology. 2010; 58(1): 70-73 | | [Pubmed] | | | 14 |
Retinopathy of prematurity: Clinical insights from molecular studies |
|
| Heidary, G., Löfqvist, C., Mantagos, I.S., Vanderveen, D.K., Hellström, A., Smith, L.E. | | NeoReviews. 2009; 10(11): e550-e557 | | [Pubmed] | | | 15 |
New therapeutic approaches in the treatment of retinopathy of prematurity | [Neue therapeutische Ansätze in der Behandlung der Frü hgeborenenretinopathie] |
|
| Jandeck, C. | | Klinische Monatsblatter fur Augenheilkunde. 2009; 226(11): 914-920 | | [Pubmed] | | | 16 |
Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema |
|
| | | Ophthalmology. 2009; 116(8): 1488 | | [VIEW] | | | 17 |
Effect of intravitreal bevacizumab (Avastin) on the growing rabbit eye |
|
| Axer-Siegel, R., Herscovici, Z., Hasanreisoglu, M., Kremer, I., Benjamini, Y., Snir, M. | | Current Eye Research. 2009; 34(8): 660-665 | | [Pubmed] | | | 18 |
A Systematic Analysis of the Off-Label Use of Bevacizumab for Severe Retinopathy of Prematurity |
|
| Micieli, J.A., Surkont, M., Smith, A.F. | | American Journal of Ophthalmology. 2009; 148(4): 536-543, e2 | | [Pubmed] | | | 19 |
Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular Edema. The Pan-American Collaborative Retina Study Group at 24 Months |
|
| Arevalo, J.F., Sanchez, J.G., Wu, L., Maia, M., Alezzandrini, A.A., Brito, M., Bonafonte, S., (...), Udaondo-Mirete, P. | | Ophthalmology. 2009; 116(8): 1488-1497,e1 | | [Pubmed] | | | 20 |
Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up |
|
| Arevalo, F., Sanchez, J.G., Fromow-Guerra, J., Wu, L., Berrocal, M.H., Farah, M.E., Cardillo, J., Rodríguez, F.J. | | Graefeæs Archive for Clinical and Experimental Ophthalmology. 2009; 247(6): 735-743 | | [Pubmed] | | | 21 |
Retinopathy of Prematurity |
|
| Askin, D.F., Diehl-Jones, W. | | Critical Care Nursing Clinics of North America. 2009; 21(2): 213-233 | | [Pubmed] | | | 22 |
Bevacizumab (Avastin) for the Treatment of Ocular Disease |
|
| Gunther, J.B., Altaweel, M.M. | | Survey of Ophthalmology. 2009; 54(3): 372-400 | | [Pubmed] | | | 23 |
Antivascular endothelial growth factor for retinopathy of prematurity |
|
| Mintz-Hittner, H.A., Best, L.M. | | Current Opinion in Pediatrics. 2009; 21(2): 182-187 | | [Pubmed] | | | 24 |
Emerging treatments for retinopathy of prematurity |
|
| Mantagos, I.S., Vanderveen, D.K., Smith, L.E.H. | | Seminars in Ophthalmology. 2009; 24(2): 82-86 | | [Pubmed] | | | 25 |
Anatomical and visual outcome of stages 4 and 5 retinopathy of prematurity |
|
| Shah, P.K., Narendran, V., Kalpana, N., Tawansy, K.A. | | Eye. 2009; 23(1): 176-180 | | [Pubmed] | | | 26 |
Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. |
|
| MINTZ-HITTNER, H.A. and KUFFEL JR, R.R. | | Retina. 2008; 28(6): 831 | | [Pubmed] | | | 27 |
Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization |
|
| Mansour, A.M. and Mackensen, F. and Arevalo, J.F. and Ziemssen, F. and Mahendradas, P. and Mehio-Sibai, A. and Hrisomalos, N. and Lai, T.Y.Y. and Dodwell, D. and Chan, W.M. and others | | American Journal of Ophthalmology. 2008; 146(3): 410-416 | | [Pubmed] | | | 28 |
Intravitreal bevacizumab for neovascular glaucoma |
|
| Andrijević-Derk, B., Vatavuk, Z., Benčić, G., Novak-Lauš, K., Mandić, Z. | | Acta Clinica Croatica. 2008; 47(3): 175-179 | | [Pubmed] | | | 29 |
Surgical management of retinopathy of prematurity |
|
| Hubbard, G.B. | | Current Opinion in Ophthalmology. 2008; 19(5): 384-390 | | [Pubmed] | | | 30 |
Effect of bevacizumab (avastin) on eye diseases |
|
| Song, H., Ren, B., Gao, X.-W. | | International Journal of Ophthalmology. 2008; 8(6): 1230-1232 | | [Pubmed] | | | 31 |
Retinal detachment in children: Differential diagnosis and current therapy | [Netzhautablösung im kindesalter: Differenzialdiagnose und aktuelle therapieoptionen] |
|
| Meier, P. | | Klinische Monatsblatter fur Augenheilkunde. 2008; 225(9): 779-790 | | [Pubmed] | | | 32 |
Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity |
|
| Honda, S., Hirabayashi, H., Tsukahara, Y., Negi, A. | | Graefeæs Archive for Clinical and Experimental Ophthalmology. 2008; 246(7): 1061-1063 | | [Pubmed] | | | 33 |
Progress of researches on Avastin in ophthalmology |
|
| Yu, T.-L., Bi, H.-S. | | International Journal of Ophthalmology. 2008; 8(4): 810-812 | | [Pubmed] | | | 34 |
Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population |
|
| Kumar, A. and Sinha, S. | | Indian Journal of Ophthalmology. 2007; 55(6): 451 | | [Pubmed] | | | 35 |
The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration |
|
| Azad, R. and Chandra, P. and Gupta, R. | | Indian Journal of Ophthalmology. 2007; 55(6): 441 | | [Pubmed] | | | 36 |
The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice |
|
| Hussain, N. and Ghanekar, Y. and Kaur, I. | | Indian Journal of Ophthalmology. 2007; 55(6): 445 | | [Pubmed] | | | 37 |
Combination of laser photocoagulation and intravitreal bevacizumab (Avastin{\textregistered}) for aggressive zone I retinopathy of prematurity |
|
| Chung, E.J. and Kim, J.H. and Ahn, H.S. and Koh, H.J. | | Graefeæs Archive for Clinical and Experimental Ophthalmology. 2007; 245(11): 1727-1730 | | [Pubmed] | | | 38 |
Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity |
|
| Azad, R., Chandra, P. | | Indian Journal of Ophthalmology. 2007; 55(4): 319 | | [Pubmed] | | | 39 |
Authorsæ reply |
|
| Shah, P.K., Narendran, V., Tawansy, K.A., Raghuram, A., Narendran, K. | | Indian Journal of Ophthalmology. 2007; 55(4): 317-318 | | [Pubmed] | | | 40 |
Intravitreal bevacizumab (Avastin) for post-laser photocoagulation anterior segment ischemia in aggressive posterior retinopathy of prematurity |
|
| Sangtam, T., Vinekar, A., Maheshwar, B., Dogra, M.R., Eong, K.-G.A. | | Indian Journal of Ophthalmology. 2007; 55(4): 317 | | [Pubmed] | | | 41 |
Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries |
|
| Velpandian, T. and Sharma, C. and Garg, SP and Mandal, S. and Ghose, S. | | Indian Journal of Ophthalmology. 2007; 55(6): 488 | | [Pubmed] | | | 42 |
Off-label use of medicines: Medical research and medical practice |
|
| Khamar, B. | | Indian Journal of Ophthalmology. 2007; 55(6): 411 | | [Pubmed] | | | 43 |
Intravitreal bevacizumab: an analysis of the evidence |
|
| Smit, D.P. and Meyer, D. | | Clinical Ophthalmology. 2007; 1(3): 273-284 | | [Pubmed] | | | 44 |
Bevacizumab for ophthalmic diseases |
|
| Stephan Michels, Franz Prager, Sophie J Bakri, Joachim Wachtlin | | Expert Review of Ophthalmology. 2007; 2(3): 369 | | [VIEW] | |
|
|
|
|
|
|
|
|
